

Simple UV Spectrophotometric Assay of Atorvastatin API Formulation and their Comparative Study

Dr. Safila Naveed¹ and Dr. Safila Naveed²

¹ Faculty of Pharmacy Jinnah University for women Karachi

Received: 6 December 2013 Accepted: 5 January 2014 Published: 15 January 2014

6

Abstract

A rapid, simple, accurate, and economical least time consuming rosuvastatin spectrophotometric method has been developed for the assay of atorvastatin and then compare assay of brand available in Karachi, Pakistan. The assay is based on the ultraviolet UV absorbance maxima at about 244nm wavelength of atorvastatin using methanol as solvent. A sample of drug was dissolved in methanol to produce a solution containing atorvastatin. Similarly, a sample of ground tablets of different brand were extracted with methanol and diluted with the same methanol. The absorbance of sample preparation was measured at 244 nm against the solvent blank and the assay was determined by comparing with the absorbance of available brand. The method can be applied for the routine QC quantitation of atorvastatin in tablet formulation and active.

18

19 **Index terms**— atorvastatin, assay, uv pectrophotometry.

20 1 Introduction

21 torvastatin figure 1 is an HMG-CoA reductase inhibitors (3-hydroxy,3-methylglutaryl-CoA), called statins. It 22 was a breakthrough for the prevention of hypercholesterolemia and related diseases.1-3 Cholesterol has an 23 important role in the daily functioning of the body. But, it can also have a negative effect to the development of 24 atherosclerosis. These plaques can block the arteries, disturb blood flow, or may rupturing and causing a clot that 25 increases blockage. The results of these blockages are very serious and can cause angina, claudication, stroke and 26 heart attack.4 Hyperlipidemia and hypertension are correlated to each other and have additional effect on CHD 27 coronary heart disease and associated mortality rate, since CV cardiovascular disease is closely related to some 28 factors such as high cholesterol levels, hypertension or diabetes. In literature there are many evidences which 29 suggest additive beneficial effects of statin combined with losartan in the treatment of hypercholesterolemia, 30 hypertensive patients.5

31 There are several methods reported by HPLC with the statin 6-10 but there is study found that show 32 the comparison of available brands in market. Because the therapy is very expensive an person who has any 33 cardiovascular disorder take medicine life time when he started. Therefor it is important that they use medicine 34 should not be expensive and give hundred % result.

35 Author: Faculty of Pharmacy Jinnah University for Women Karachi. e-mail: safila117@yahoo.com There for 36 in the mind of this I have checked the % assay of different brands available in the market .

37 The aim of this study is to investigate the assay of commercially available six brands of atorvastatin in Karachi, 38 Pakistan. number and were labeled to conatin atorvastatin 10mg per tablet. All the six brands have 5 year shelf 39 life.

40 The serial number as an identification of purchased brands are given in Tabel 1.20 tablets of six different brand 41 of atorvastatin from the marketed sample were weighed and crushed uniformly with the help of a mortar and 42 pestle. By calculating the average weighed sample powder equivalent to 10 mg of atorvastatin was transferred 43 into a volumetric flask containing 10mL methanol solvent MeOH. The solutions were sonicated for about 5 min 44 and than make up volume upto 100 ml with water.

4 RESULTS AND DISCUSSIONS

45 2 d) Procedure

46 After preparation of standard and tablet solutions, strength of solution 100 ppm in 100 ml absorbance of the
47 sample preparation and standard preparation in 1cm cell at the wavelength of maximum absorbance at about
48 244 nm, using spectrophotometer, using the blank solution. Calculate the quantity in mg, of atorvastatin per
49 tablet.

50 3 III.

51 4 Results and Discussions

52 Pharmaceutical assay was carried out by using spectrophotometer on all brands of atorvastatin tablets during
53 the study. Table-1 shows name brand and % assay of different brands. Table-2 ,3 are showing the descriptive
54 within and between groups and shows result are highly significant with p value 0.000.

55 Test of hypothesis i-e ANOVA and multiple comparison of different brands of atorvastatin are given in table
56 ?? shows highly significant difference of all brands with each other. The proposed method for the assay of
57 commercially available atorvastatin tablet formulation is very simple, accurate ,least time consuming and rapid.
58 It can be easily used for routine quality control QC for monitoring the assay in the API, inprocess samples and
59 tablet formulation. ANOVA shows between and within group F value 309348.804 with degree of freedom df
value5 and 24 and p value 0.00 which shows significant results. ¹



1

Figure 1: Figure 1 :

1

Brand Name	Serial no	Average wt of tablet mg	Wt for 100 ppm	Absorbance 244 nm	% assay
Prostatin	ATR-1	16.43	16.43	0.157	104.66
Statin	ATR-2	16.6	16.6	0.137	91.33
Fopsec	ATR-3	15.9	15.9	0.099	66.00
Winstor	ATR-4	15.6	15.6	0.118	78.66
Survive	ATR-5	18.8	18.8	0.059	39.33

Figure 2: Table 1 :

2

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	13328.351	5	2665.670	309348.80400	
Within Groups	.207	24	.009		
Total	13328.557	29			

Figure 1

Figure 3: Table 2 :

60


5

Figure 4: Table 5 :

4 RESULTS AND DISCUSSIONS

61 [Tobert ()] , J A Tobert . *Nat. Rev. Drug Discov* 2003. 2 p. .

62 [Jones et al. ()] , P H Jones , M H Davidson , E A Stein , H E Bays , J M Mckenney , E Miller . *Am. J. Cardiol*
63 2003. 92 p. .

64 [Caslake et al. ()] , M J Caslake , G Stewart , S P Day , E Daly . *Atherosclerosis* 2003. 171 p. .

65 [Koh et al. ()] , K K Koh , M J Quon , S H Han . *J. Am. Heart Assoc* 2004. 110 p. .

66 [Mckenney ()] , J M Mckenney . *Am. J. Health-Syst. Pharm* 2005. 62 p. .

67 [Sultana et al. ()] 'Determination of Enalapril and Statins In Pharmaceutical Formulations by RP-HPLC'. N
68 Sultana , Arayne Ms , Safila Naveed . *Chilean chemical society* 2011. 56 (3) p. .

69 [Sultana et al. ()] 'Simultaneous Determination of Captopril and Statins in API, Pharmaceutical Formulations
70 and in Human Serum by RP-HPLC'. N Sultana , M S Arayne , Safila Naveed . *J. Chin. Chem. Soc* 2010. 57
71 p. .

72 [Sultana et al. ()] 'Simultaneous determination of Prazosin, Atorvastatin, Rosuvastatin and Simvastatin in API,
73 Dosage Formulations and Human serum by RP-HPLC'. N Sultana , M S Arayne , S N Shah , Safila Naveed
74 . *Journal of the Chinese Chemical Society* 2010. 57 (6) p. .

75 [Arayne et al. ()] 'Simultaneous LC Determination of Rosuvastatin, Lisinopril, Captopril, and Enalapril in API'.
76 M S Arayne , N Sultana , Arman Tabassum . 10.1007/s00044-012-9997-. *Pharmaceutical Dosage Formulations,*
77 *and Human Serum Medicinal Chemistry Research* Saeeda Nadir Ali and Safila Naveed (ed.) 2012. 21 p. .

78 [Sultana et al. ()] 'Validated Method for the Simultaneous Determination of Lisinopril, Pravastatin, Atorvastatin
79 and Rosuvastatin in API, Formulations and Human Serum by RP-HPLC Chinese'. N Sultana , Arayne Ms ,
80 Safila Naveed . 10.1002/cjoc.201190226. *Journal of Chemistry* 2011. 29 p. .